JOURNAL DESCRIPTION
The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.
Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.
Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.
The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.
Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.
The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.
Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.
The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.
Medical Radiology and Radiation Safety. 2021. Vol. 66. № 5. P. 39–44
Search of Predictors of Radiosensitivity in Rectal Adenocarcinoma
M.A. Vologirova1, N.N. Volchenko1, I.V. Droshneva1, I.A. Zamulaeva2, A.V. Boyko1, D.V. Sidorov1
1P.A. Hertsen Moscow Oncology Research Institute, Moscow, Russia
2A.P. Tsyb Medical Radiological Research Center, Obninsk, Russia
Contact person: Milana Aslanovna Vologirova: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Purpose: To analyze a number of immunohistochemical markers as predictors of the radiosensitivity of rectal adenocarcinoma.
Material and methods: The study included 122 patients with histologically verified rectal adenocarcinoma, varying degrees of differentiation, and the stage of the tumor process I-IIIС, T2-T4b /N0-N2b/ M0, with the localization of the tumor in the lower-middle-ampullary parts of the rectum. Predictors included in the research: Ki67, р53, EGFR, Bcl2, COX2, P21, E-cadherin. Preoperative chemoradiotherapy was performed up to 48–50 Gy with the use of medications (5-FU, Cisplatin) as a radio modifiers. The analysis was carried out according to the degree of severity of therapeutic pathomorphosis (according to Mandard), a decrease in the stage before surgery.
Results: A full course of preoperative chemoradiotherapy followed by surgery was performed at 121 patients, one patient died of concomitant cardiac pathology during the break. The first degree of Mandard pathomorphosis (complete resorption) registered at 12 patients. The second degree (preservation of a few tumor cells against the background of fibrotic changes) – at 27 patients. The third degree (a large number of preserved tumor cells against the background of the predominance of fibrosis) – at 38 patients. The fourth degree (tumor cells predominate over fibrotic changes) – at 27 patients. The fifth degree (complete absence of signs of tumor regression, absence of fibrosis) – at 2 patients. A decrease in the stage of the tumor process according to the preoperative comprehensive examination registered in 114 (94.2%) patients, in 9 (7.4%) patients – there was no dynamics. During the observation period from 2006 until nowadays, 10 people are known to have died. Years in remission range from 3 months to 22 years. According to the results of multivariate and multiple regression analyses, it is possible to successfully predict the effectiveness of chemoradiotherapy, both with the use of biomarkers (Ki67, р53, EGFR, Bcl2, COX2, P21, E-cadherin), and traditional indicators (histological type, stage of the disease, gender, degree of differentiation). It turned out, that both traditional indicators and immunohistochemical indicators work equally well, regardless of each other.
Conclusion: Studied immunohistochemical predictors of radiosensitivity of rectal adenocarcinoma, allow to assess the degree of radiosensitivity or radioresistance of the tumor in each patient before the start of preoperative chemoradiotherapy by doing so, it warns us about the effectiveness or ineffectiveness of chemoradiotherapy in a specific clinical situation, which allows us to individualize the approach to treatment, choosing a more suitable treatment method for the patient: neoadjuvant chemotherapy or surgery.
Key words: locally advanced rectal cancer, preoperative chemoradiotherapy, therapeutic pathomorphosis, radiosensitivity predictors
For citation: Vologirova MA, Volchenko NN, Zamulaeva IA, Sidorov DV, Boyko AV, Droshneva IV. Search of Predictors of Ra6iosensitivity in Rectal Adenocarcinoma. Medical Radiology and Radiation Safety. 2021;66(5):39-44.
DOI: 10.12737/1024-6177-2021-66-5-39-44
References
1. Sidorov D. V., 2011. Doctoral Dissertation: "Role of Total Mesorectumectomy in the Surgical and Combined Treatment of Patients with Rectal Cancer". (In Russian.).
2. Bailey C.E., Hu C.-Y., You Y.N., et al. 2015. Increasing Disparities in the Age-Related Incidences of Colon and Rectal Cancers in the United States, 1975–2010. JAMA Surg, 2015;150;1:17-22. https://doi.org/10.1001/jamasurg.2014.1756
3. Kaprin A.D., Starinsky V. V., Petrova G. V. State of Cancer Care in Russia in 2018. 2019; P. 80 (In Russian.).
4. Chernikovsky I. L. Multidisciplinary Approach to the Diagnosis and Treatment of Resectable Rectal Cancer. Practikal Oncology. 2015; 16. (2): 69-76. (In Russian.).
5. Rasulov A. O., 2012 Doctoral Dissertation: "Surgical Tactics after Chemoradiotherapy of Rectal Cancer". (In Russian).
6. Chernichenko M. A., 2016. PhD Thesis: "Optimization of Surgical and Combined Treatment of Patients with Lower Ampullary Rectal Cancer". P. 84, 121. (In Russian.).
7. Giralt J, Eraso A, Armengol M, Rossello J, et al. Epidermal Growth Factor Receptor of Tumor Response in Locally Advanced Rectal Cancer Patients Treated with Preoperative Radiotherapy. Int J Radiat Oncol Biol Phys 2002;54:1460-5. https://doi.org/10.1016/s0360-3016(01)01842-9.
8. Rau B, Sturm I, Lage H, Berger S, Schneider U, Hauptmann S, et al. Dynamic Expression Profile of P21waf1/Cip1 and Ki-67 Predicts Survival in Rectal Carcinoma Treated with Preoperative Radiochemotherapy. J Clin Oncol 2003;21:3391-401. https:// doi.org/10.1200/jco.2003.07.077.
9. Smith FM, Reynolds JV, Miller N, Stephens RB, Kennedy MJ. 2005. Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy. European Journal of Surgical Oncology: the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 01 Dec 2005, 32(1):55-64. https://doi.org/10.1016 /j.ejso.2005.09.010
10. Negri FV 1, Campanini N, Camisa R, Pucci F, Bui S, Ceccon G, Martinelli R, Fumagalli M, Losardo PL, Crafa P, Bordi C, Cascinu S, Ardizzoni A. Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy. British Journal of Cancer, 98:143–147. 2008 Jan 15. https://doi.org/10.1038/sj.bjc.6604131.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The author declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors
Article received: 18.01.2021.
Accepted for publication: 25.03.2021.